Protocol Ledger

NCT03599713 · Phase II · COMPLETED

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

Interventional Phase II clinical trial protocol NCT03599713 sponsored by Incyte in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-02-25 Enrollment: 107 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03599713
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)107 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03599713
Protocol FieldVerified Registry Value
NCT IdentifierNCT03599713
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment107 participants (ACTUAL)
Registered Start Date2019-02-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI